CERo Therapeutics (CERO) said Tuesday that the US Food and Drug Administration has granted orphan drug designation for its lead drug candidate, CER-1236, for acute myeloid leukemia.
Shares jumped over 220% as intraday trading volume advanced to over 51.2 million from a daily average of about 101,000.
Acurx Pharmaceuticals (ACXP) said its lead antibiotic candidate, ibezapolstat, is ready to advance to international phase 3 clinical trials to treat patients with C. difficile infection.
Shares soared over 130% as intraday trading volume surged to more than 309 million from a daily average of roughly 182,000.
Eli Lilly (LLY) said that it agreed to acquire Verve Therapeutics (VERV) for up to about $1.3 billion to advance gene-editing therapies for cardiovascular disease.
Verve shares soared 78%, with intraday trading volume of more than 72.5 million against a daily average of about 3.49 million.
Price: 22.04, Change: +15.18, Percent Change: +220.97
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.